History of the Development of Sucralfate
Sucralfate was introduced in Japan as a selective ulcer-protecting agent in 1968 and it is currently accepted worldwide as a nonsystemic site protector. This agent has an unusual developmental history among the drugs for peptic ulcer disease (PUD). The development of sucralfate is a true reflection of international collaboration.
KeywordsDuodenal Ulcer Gastric Ulcer Ulcer Healing Nosocomial Pneumonia Gastric Mucus
Unable to display preview. Download preview PDF.
- 7.Marks IN: A skeptical view of medical treatment, in Truelove SC, Willoughby CP (eds): Topics in Gastroenterology. Oxford, Blackwell, vol 7, pp 111–129, 1979. Sucralfate has comparable efficacy to cimetidine in healing gastroduodenal ulcers.Google Scholar
- 9.Moshal MG, Spitaels J-M, Manion GL: Double-blind placebo-controlled evaluation of one year therapy with sucralfate on healed duodenal ulcer. Scand J Gastroenterol 18(suppl 83):57–59, 1983. Sucralfate is superior to placebo in keeping DU in remission.Google Scholar
- 10.Bigley LD, Giesing D: Studies on acting mechanism of sucralfate, in Caspary WF (ed): Duodenal Ulcer, Gastric Ulcer: Sucralfate. Munich, Urban &0026; Schwarzenberg, 1981, pp 3–12.Google Scholar
- 12.Steiner K, Garbe A: Specific binding of 14C-sucralfate to acetic acid-induced gastric and duodenal ulcers of the rat, in Caspary WF (ed): Duodenal Ulcer, Gastric Ulcer: Sucralfate. Munich, Urban &0026; Schwarzenberg, 1981, pp 19–21.Google Scholar
- 13.Sasaki H, Hinohara Y, Tsunoda Y, et al: Binding sucralfate to duodenal ulcer in man. Scan J Gastroenterol 18(suppl 83):13–14, 1983.Google Scholar
- 14.Quinton A: Binding duration of sucralfate assessed at different doses. International update: GL therapy, Maui, 1987. References 10–14 discuss binding of sucralfate to the base of peptic ulcers.Google Scholar
- 15.Nagashima R, Hirano T: Selective binding of sucralfate to ulcer lesion. Arzneim Forsch 30:80–83, 1980. This study illustrates the selective binding of sucralfate to an ulcer base.Google Scholar
- 17.Driks MR, Craven DE, Celli BR, et al: Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine-type 2 blockers. N Engl J Med 317:1376–1382. 1987. Nosocomial pneumonia was thought to occur more often after H2RA therapy of intubated patients.PubMedCrossRefGoogle Scholar